IGC Pharma (IGC)
XASE:IGC
Top Page
IGC Pharma
(NYSE MKT:IGC)
Select Model
Select Model
Rating:44Neutral
Price Target:
$0.25
▼(-17.67% Downside)
Action:ReiteratedDate:03/31/26
The score is primarily held down by weak financial performance, driven by severe losses and negative cash flow despite low leverage. Technicals also indicate a weak trend with price below major moving averages and negative MACD. Corporate events add modest support through increased visibility and added liquidity, but valuation remains constrained by the company’s loss-making profile.
Positive Factors
Low Leverage / Balance Sheet Strength
Very low debt-to-equity (~0.02) reduces refinancing and solvency risk, giving the company structural financial flexibility. For a cash-burning clinical-stage biotech, low leverage lowers the probability of immediate solvency stress and preserves optionality to raise capital under less pressured terms over the next several months.
Negative Factors
Persistent Cash Burn
Material negative operating and free cash flow (~-$5.5M to -$5.8M TTM) imply the company must rely on external financing to sustain operations. Persistent burn drains time and increases dilution risk; absent near-term cash flow improvement, resource constraints could slow clinical programs and strategic execution.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage / Balance Sheet Strength
Very low debt-to-equity (~0.02) reduces refinancing and solvency risk, giving the company structural financial flexibility. For a cash-burning clinical-stage biotech, low leverage lowers the probability of immediate solvency stress and preserves optionality to raise capital under less pressured terms over the next several months.
Read all positive factors
IGC Pharma (IGC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$27.66M
Dividend YieldN/A
Average Volume (3M)715.71K
Price to Earnings (P/E)―
Beta (1Y)0.48
Revenue Growth-6.51%
EPS Growth58.31%
CountryUS
Employees67
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.01
Shares Outstanding98,796,090
10 Day Avg. Volume826,885
30 Day Avg. Volume715,709
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)3.45
Price to Sales (P/S)17.16
P/FCF Ratio-4.13
Enterprise Value/Market Cap1.05
Enterprise Value/Revenue24.17
Enterprise Value/Gross Profit72.27
Enterprise Value/Ebitda-3.81
Forecast
1Y Price Target
$5.00Price Target Upside1566.67% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.09
Revenue Forecast (FY)$1.10M
IGC Pharma Business Overview & Revenue Model
Company Description
IGC Pharma, Inc. is a clinical-stage pharmaceutical company that is focused on Alzheimer's disease, developing innovative solutions to address this devastating illness. It has two investigational drug assets targeting Alzheimer's disease: IGC-AD1,...
How the Company Makes Money
null...
IGC Pharma Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
63
Positive
Cash Flow
25
Negative
| Breakdown | TTM | Mar 2025 | Mar 2024 | Jun 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.20M | 1.27M | 1.34M | 911.00K | 397.00K | 898.00K |
| Gross Profit | 401.00K | 619.00K | 733.00K | -158.00K | 194.00K | -349.00K |
| EBITDA | -7.60M | -6.83M | -9.16M | -10.85M | -14.37M | -8.33M |
| Net Income | -5.34M | -7.12M | -13.00M | -11.51M | -15.02M | -8.81M |
Balance Sheet | ||||||
| Total Assets | 9.71M | 8.75M | 9.90M | 17.18M | 26.83M | 35.87M |
| Cash, Cash Equivalents and Short-Term Investments | 938.00K | 405.00K | 1.20M | 3.35M | 10.46M | 14.63M |
| Total Debt | 142.00K | 238.00K | 348.00K | 481.00K | 611.00K | 1.07M |
| Total Liabilities | 2.29M | 2.42M | 2.58M | 2.27M | 2.94M | 3.06M |
| Stockholders Equity | 7.42M | 6.33M | 7.32M | 14.91M | 23.89M | 32.80M |
Cash Flow | ||||||
| Free Cash Flow | -5.78M | -5.28M | -5.71M | -7.67M | -8.23M | -12.39M |
| Operating Cash Flow | -5.45M | -4.79M | -5.20M | -7.05M | -7.46M | -10.80M |
| Investing Cash Flow | -164.00K | -442.00K | -317.00K | -235.00K | -742.00K | 3.39M |
| Financing Cash Flow | 6.03M | 4.45M | 3.52M | 100.00K | 4.14M | 14.69M |
IGC Pharma Technical Analysis
Positive
0.30
Price Trends
0.27
Positive
0.29
Negative
0.34
Negative
Market Momentum
>-0.01
Negative
54.29
Neutral
60.05
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IGC, the sentiment is Positive. The current price of 0.3 is above the 20-day moving average (MA) of 0.27, above the 50-day MA of 0.27, and below the 200-day MA of 0.34, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 54.29 is Neutral, neither overbought nor oversold. The STOCH value of 60.05 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IGC.
IGC Pharma Risk Analysis
IGC Pharma disclosed 37 risk factors in its most recent earnings report. IGC Pharma reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
IGC Pharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $48.77M | 0.54 | -225.83% | ― | -14.92% | 72.81% | |
48 Neutral | $32.53M | -4.16 | -695.82% | ― | -0.66% | -8.43% | |
47 Neutral | $99.98M | -4.95 | 252.30% | ― | 234.73% | 81.16% | |
44 Neutral | $27.66M | -9.21 | -96.36% | ― | -6.51% | 58.31% | |
40 Underperform | $33.77M | -1.06 | 280.42% | ― | 121.74% | 24.75% |
* Healthcare Sector Average
IGC
IGC Pharma
0.28
0.01
4.09%
PLUR
Pluri
3.36
-0.38
-10.16%
DYAI
Dyadic International
0.89
-0.31
-25.67%
VRCA
Verrica Pharmaceuticals
5.82
1.39
31.50%
ELUT
Elutia
1.14
-1.10
-49.11%
IGC Pharma Corporate Events
Business Operations and Strategy
IGC Pharma Launches National Media Partnership to Boost Visibility
Positive
Mar 31, 2026
On March 30, 2026, IGC Pharma announced a 12-part strategic national media partnership with financial media platform New to The Street to bolster its investor relations and corporate communications. The collaboration aims to expand visibility amon...
Business Operations and StrategyPrivate Placements and Financing
IGC Pharma Secures New Debt Financing for Liquidity
Positive
Mar 12, 2026
On March 5, 2026, IGC Pharma, Inc. entered into a Securities Purchase Agreement with Vanquish Funding Group Inc., issuing a $353,050 promissory note, including a $46,050 original issue discount, for a purchase price of $307,000 maturing on Februar...
Business Operations and StrategyPrivate Placements and Financing
IGC Pharma Announces Registered Direct Equity Offering Financing
Neutral
Jan 6, 2026
On January 5, 2026, IGC Pharma, Inc. entered into a subscription agreement with a group of investors for a registered direct offering of 779,997 shares of common stock at $0.30 per share, raising approximately $234,000 in gross proceeds before exp...
Business Operations and StrategyRegulatory Filings and Compliance
IGC Pharma Adjusts Fiscal Year-End to December 31
Neutral
Jan 2, 2026
On December 30, 2025, IGC Pharma, Inc. announced that its Board of Directors approved a change in the company’s fiscal year-end from March 31 to December 31, effective December 31, 2025. To accommodate this shift, the company plans to file a...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.